Text anzeigen (PDF) - bei DuEPublico

Literatur 106
112) Nakamura Y, Takeda M , Suzuki H, Hattori H, Tada K, Hariguchi S, Hashimoto S, Nishimura T
(1991): Abnormal distribution of Cathepsins in the brain of patients with Alzheimer's disease. Neurosci
Lett 130, 195-8.
113) Nakano K, Ohta S, Nishimaki K, Miki T, Matuda S (1997): Alzheimer's disease and DLST genotype.
Lancet 350, 1367-8.
114) Namekata K, Imagawa M, Terashi A, Ohta S, Oyama F, Ihara Y (1997): Association of transferrin C2
allele with late-onset Alzheimer's disease. Hum Genet. 101, 126-9.
115) Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar
D, Love S, Moss T, Griffin WS (2000): Association of interleukin-1 gene polymorphisms with Alzheimer's
disease. Ann Neurol.47, 365-8.
116) Nixon RA, Mathews PM, Cataldo AM (2001): The neuronal endosomal-lysosomal system in Alzheimer's
disease. J Alzheimers Dis. 3, 97-107.
117) Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003): Amyloid deposition precedes
tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging. 24, 1063-70.
118) Okuizumi K, Onodera O, Namba Y, Ikeda K, Yamamoto T, Seki K, Ueki A, Nanko S, Tanaka H,
Takahashi H, Oyanagi K, Mizusawa H, Kanazawa I, Tsuji S (1995): Genetic association of the very
low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat Genet 11, 207-
9.
119) Ott A, van Rossum CT, van Harskamp F, van de Mheen H, Hofman A, Breteler MM (1999): Education
and the incidence of dementia in a large population-based study: The Rotterdam Study. Neurology.
52, 663-66.
120) Ott BR (2002): Medical treatment of Alzheimer's disease: past, present, and future. Med Health R.I.
85, 210-2.
121) Panegyres PK, Mamotte CD, Vasikaran SD, Wilton S, Fabian V, Kakulas BA (1999): Butyrycholinesterase
K variant and Alzheimer's disease. J Neurol. 246, 369-70.
122) Papassotiropoulos A, Bagli M, Feder O, Jessen F, Maier W, Rao ML, Ludwig M, Schwab SG, Heun
R (1999): Genetic polymorphism of Cathepsin D is strongly associated with the risk for developing
sporadic Alzheimer's disease. Neurosci Lett 262, 171-4.
123) Papassotiropoulos A, Bagli M, Kurz A, Kornhuber J, Forstl H, Maier W, Pauls J, Lautenschlager N,
Heun R (2000a): A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease. Ann
Neurol. 47, 399-403.
124) Papassotiropoulos A, Bagli M, Becker K, Jessen F, Maier W, Rao ML, Ludwig M, Heun R (2000b):
No association between an intronic biallelic polymorphism of the FE65 gene and Alzheimer's disease.
Int J Mol Med. 6, 587-9.
125) Papassotiropoulos A, Lewis HD, Bagli M, Jessen F, Ptok U, Schulte A, Shearman MS, Heun R
(2002): Cerebrospinal fluid levels of beta-amyloid(42) in patients with Alzheimer's disease are related
to the exon 2 polymorphism of the Cathepsin D-Gene. Neuroreport 13, 1291-4.
126) Payami H, Schellenberg GD, Zareparsi S, Kaye J, Sexton GJ, Head MA, Matsuyama SS, Jarvik LF,
Miller B, McManus DQ, Bird TD, Katzman R, Heston L, Norman D, Small GW (1997): Evidence for
association of HLA-A2 allele with onset age of Alzheimer's disease. Neurology 49, 512-8.
127) Prince JA, Feuk L, Sawyer SL, Gottfries J, Ricksten A, Nagga K, Bogdanovic N, Blennow K, Brookes
AJ (2001): Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms
in prior candidate genes for sporadic Alzheimer's disease. Eur J Hum Genet. 9, 437-44.